Clinical Rheumatology最新文献

{"title":"Hyperuricemia in psoriatic arthritis: clinical correlations and implications.","authors":"Samar AbdAlhamed Tabra, Hany M Aly, Saad Ghanem, Mohammed Hassan Abu-Zaid","doi":"10.1007/s10067-025-07400-4","DOIUrl":"10.1007/s10067-025-07400-4","url":null,"abstract":"<p><strong>Background: </strong>Psoriatic arthritis (PsA) patients may have elevated serum uric acid levels, and hyperuricemia may impact the degree of inflammation and clinical disease severity.</p><p><strong>Objectives: </strong>comparison between PsA patients with and without hyperuricemia and assessment of the effect of hyperuricemia on clinical presentation, disease activity, disease severity, and associated comorbidities in PsA patients.</p><p><strong>Methods: </strong>76 PsA patients with hyperuricemia and 74 PsA patients with normal uric acid as control were included. Demographic, clinical, comorbidities, and laboratory data were collected. Hyperuricemia threshold ≥ 60 mg/L.</p><p><strong>Results: </strong>There were no significant differences between patients with and without hyperuricemia regarding gender, PsA articular subtype, PASI score, and treatment received, while patients with hyperuricemia were older (40.47 ± 8.53 vs 34.59 ± 7.29, p = 0.0001), had more comorbidity, higher body mass index (BMI) (28.49 ± 2.07 vs 26.91 ± 1.63kg/m2, p = 0.0001), DAPSA score (16.75 ± 7.04 vs 9.32 ± 6.35, p = 0.0001), ESR (34.78 ± 7.12 vs 28.55 ± 8.97, p = 0.0001), CRP (11.42 ± 3.23 vs 8.68 ± 4.04, p = 0.0001), serum cholesterol (220.42 ± 46.83 vs 169.82 ± 37.82, p = 0.0001), and triglycerides (136.47 ± 36.4 vs 104.89 ± 22.15, p = 0.0001), and longer duration of Psoriasis and PsA. The serum uric acid levels were significantly positively correlated with age, duration of Psoriasis, duration of PsA, BMI, CRP, ESR, DAPSA, and PASI score. Multivariate analysis showed that male sex, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients.</p><p><strong>Conclusion: </strong>Psoriatic arthritis patients with hyperuricemia have higher age, BMI, disease activity, and more associated comorbidities. In PsA patients, hyperuricemia was associated with male sex, BMI, and increased disease activity, but not associated with PASI score. Key Points • Psoriasis, PsA, and hyperurice s is a bi-centric case-control retrospective of cardiovascular disease. • Male gender, BMI, and increased disease activity were independent predictors of hyperuricemia in PsA patients. • Psoriatic arthritis patients with hyperuricemia have been more associated with comorbidities.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2321-2326"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the genetic components and multi-omics sources of inflammatory bowel disease from the perspective of autoimmune disorders.","authors":"Zhonghai Wang, Xin Chen, Quan-Bo Zhang, Han Wang","doi":"10.1007/s10067-025-07422-y","DOIUrl":"10.1007/s10067-025-07422-y","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) and autoimmune disorders result from immune system dysregulation. However, the genetic overlap between them remains unclear. Our study aimed to investigate the genetic mechanisms and structure of IBD from the perspective of autoimmune disorders.</p><p><strong>Methods: </strong>The genetic correlation (rg) between traits can provide valuable information about the shared underlying biological mechanisms. Utilizing summary statistics from genome-wide association studies, we delved into the genetic correlation, shared inheritance, and potential causality of IBD (N = 34,652) with autoimmune disorders (N = 1,755,610). We performed transcriptomics at the gene level, multi-marker analyses of genome annotations, and enrichment analyses of biological pathways to highlight shared and diverse perspectives.</p><p><strong>Results: </strong>There were significant genetic correlations between IBD and ankylosing spondylitis (rg = 0.327), rheumatoid arthritis (rg = 0.242), type 1 diabetes (rg = - 0.061), psoriasis (rg = 0.246), and ankylosing spondylitis (rg = 0.308). We identified 110 unique regions (including 5p33.3, 10q25.3, and 22q13.31) after a consistent study at the gene levels. By implementing transcriptomics techniques, we discovered potential common biological mechanisms in several tissues, including blood, spleen, thyroid, and pancreas, revealing potential common biological mechanisms involving lincRNA, protein-coding, and pseudogenes.</p><p><strong>Conclusion: </strong>Our study demonstrated hypothesized pleiotropic genomic regions that provide important clues to delve into the genetic basis of IBD and autoimmune disorders on the basis of multi-omics. Moreover, we have identified shared pathogenic processes and potential common therapeutic targets among these diseases. Key Points • The finding provides a new perspective on the genetic basis of inflammatory bowel disease and autoimmune disease across multi-omics platforms. • Fine mapping of functional summary-based imputation and causal genomes has identified hypothesized pleiotropic genomic regions. • The identified genes and pathways may offer innovative targets for the prevention of immune-related diseases.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2527-2539"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relevance of complement levels in assessing the activity of lupus nephritis of different pathological types.","authors":"Weiji Xie, Yixin Zhang, Shiting He, Xuewan Lin, Shuping Zhao, Zeen Xiao, Yimin Zhang","doi":"10.1007/s10067-025-07429-5","DOIUrl":"10.1007/s10067-025-07429-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease that predominantly affects women of childbearing age. Lupus nephritis (LN) is a relatively common and serious complication in clinical patients. The aim of this study was to evaluate the correlation of complement levels and SLEDAI- 2000 (SLEDAI- 2 K) with renal activity in different pathological types of LN.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A total of 220 patients with SLE and LN were included. Renal active inflammation was calculated using the National Institutes of Health (NIH) Activity Index (AI) . Patients were classified into two groups based on the AI at the time of kidney biopsy: low-to-moderate-activity group with an AI &lt; 10 and high-active group with an AI ≥ 10. Laboratory indicators, including complement levels and the SLEDAI- 2 K, were collected to assess their correlation with renal activity in LN.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The average complement levels in class V LN were higher than that in class III/IV and III/IV + V LN. Serum creatinine and 24-h urine protein were lower than those in class III/IV and III/IV + V LN. Laboratory indicators, including complement levels and SLEDAI- 2 K, shown no correlation with AI in class V LN. Appropriate clinical indicators of AI in patients with class III/IV and III/IV + V LN were further assessed by ROC curves, SLEDAI- 2 K exhibiting the highest performance (AUC 0.757, 95% CI 0.687-0.817), 24-h urine protein (AUC 0.736, 95% CI 0.665-0.798), hemoglobin (AUC 0.726, 95% CI 0.655-0.789), C3 (AUC 0.676, 95% CI 0.603-0.744), serum creatinine (AUC 0.664, 95% CI 0.591-0.733), and C4 (AUC 0.660, 95% CI 0.586-0.729).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Decreased levels of complement C3 and C4 have limited predictive value as a clinical tool for assessing disease activity in patients with LN, especially in class V LN. SLEDAI- 2 K, a widely used clinical scale, correlates with disease activity in patients with class III/IV, III/IV + V LN. Serum creatinine is a clinical indicator of chronic kidney damage in patients with class III/IV, III/IV + V, and V LN. Key Points Complement levels: can they accurately assess disease activity in lupus nephritis? • Studies investigating the correlation between complement levels and disease activity in patients with SLE and LN yield inconsistent results, and the ambiguity of these findings may stem from factors such as the pathological staging of LN and individual variations in complement levels. Fewer studies in the current research on disease activity in patients with LN will be based on different pathological types of LN, which leads to limitations in the final findings. • This study aimed to analyze the feasibility of complement levels and SLEDAI- 2 K in assessing renal activity in patients with different pathological types of LN. • We assessed disease activity by obtaining AI from renal biopsies in 220 patients with LN and examined their correlation with dise","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2269-2276"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomic sequencing of multiple salivary glands combined with bioinformatics analysis reveals key genes in primary Sjögren's syndrome.","authors":"Chenchen Wang, Hongmin Hu, Yinyue Xu, Shasha Wang","doi":"10.1007/s10067-025-07428-6","DOIUrl":"10.1007/s10067-025-07428-6","url":null,"abstract":"<p><strong>Objective: </strong>Reveal key genes involved in the pathogenesis of Primary Sjögren's Syndrome (pSS) and identify new potential biomarkers and therapeutic targets.</p><p><strong>Methods: </strong>mRNA transcriptome data from pSS patients'and healthy controls'parotid and minor salivary glands were collected from the Gene Expression Omnibus (GEO) database. mRNA sequencing was performed on pSS mouse model submandibular glands. Differentially expressed genes (DEGs) were identified and core genes were screened using protein-protein interaction (PPI)networks. Validation was done through Gene Ontology (GO),Kyoto Encyclopedia of Genes and Genomes (KEGG), immune cell infiltration, heatmap, and Receiver Operating Characteristic (ROC) curve analyses, followed by external validation. Finally, review the clinical studies of drugs targeting these genes.</p><p><strong>Results: </strong>A total of 113 DEGs were identified, yielding 15core DEGs CD8 A, LCK, SYK, CD2, CD247, CD3D, LCP2, CD3G, CCR7, ITK, CXCR4, B2M, CXCL10, CXCL13, and CXCL9.These core genes were enriched in antigen receptor-mediated and T cell receptor signaling pathways, as well as in the chemokine signaling pathway. Immunocell infiltration analysis revealed that, except for B2M, the expression of other core genes is correlated with the proportion of immune cells. Genes like, CXCL13, CXCL9, CXCR4,CD2,CCR7,and ITK exhibited high diagnostic accuracy for distinguish in pSS patients. Core DEGs such as LCK, SYK, LCP2, and ITK was validated in salivary gland data from pSS patients and mouse models. Drugs targeting LCK, SYK, ITK, and other core genes, with their clinical status, were identified.</p><p><strong>Conclusion: </strong>This study identified key genes in pSS, providing novelinsights into pathogenesis, promising biomarkers, and potential therapeutictargets. Key Points • mRNA transcriptomic sequencing was conducted on submandibular gland specimens from NOD mice simulating pSS and normal mice. • Commonly dysregulated core genes were identified across the minor and parotid salivary glands of pSS patients and healthy controls, as well as in the submandibular glands of NOD and normal mice. • ROC analysis was employed to evaluate their predictive value in the diagnosis of pSS.Genes such as CXCL13, CXCL9, CXCR4, CD2, CCR7, and ITK exhibited high diagnostic accuracy for distinguishing pSS patients. • Genes such as LCK, SYK, and ITK have been validated through external verification and qPCR, and have been identified as targets for clinical drugs.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2355-2365"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical and mental disability is evident 8 years after diagnosis in early rheumatoid arthritis despite contemporary medication and non-pharmacological interventions.","authors":"Ingrid Thyberg, Magnus Husberg, Alf Kastbom","doi":"10.1007/s10067-025-07399-8","DOIUrl":"10.1007/s10067-025-07399-8","url":null,"abstract":"<p><strong>Introduction: </strong>Early interventions are known to reduce disease activity and physical disability in rheumatoid arthritis (RA), but less is known about mental health, especially in the era of early active pharmacotherapy. Consequently, we compared long-term physical and mental disability in an early RA cohort (1996-1998) with a later cohort (2006-2008).</p><p><strong>Methods: </strong>We compared 320 patients from our project Early Intervention in RA (1996-1998) (TIRA-1) with 463 patients from TIRA-2 (2006-2008). During the 8-year follow-up, pharmacotherapy and multi-professional interventions were offered according to guidelines. Disease Activity Score (DAS28), prescribed disease-modifying antirheumatic drugs (DMARDs), Health Assessment Questionnaire (HAQ), and Short Form Health Survey (SF-36) were registered yearly.</p><p><strong>Results: </strong>Significantly more patients were prescribed DMARDs in TIRA-2 than in TIRA-1, and initial improvements were seen for DAS28 and disability in both cohorts. At follow-up, TIRA-2 patients reported less physical disability (HAQ) and less mental disability (SF-36) than TIRA-1 patients. Despite improvements, 32% of the women and 21% of the men in the TIRA-2 cohort reported considerable disability (HAQ ≥ 1) at the 8-year follow-up.</p><p><strong>Conclusions: </strong>Despite improvements in our contemporarily treated TIRA-2 cohort, physical and mental disability was evident 8 years after diagnosis, especially among women. These results suggest a forthcoming need for person-centered non-pharmacological rehabilitation programs to optimize physical and mental function and to improve participation in daily life in RA. Also, the results highlight the need for developing new interventions directed at reducing disability. Key Points • Physical and mental disability is still considerable in contemporarily treated RA. • Interventions specifically aimed to reduce these disabilities need to be further developed. • Patients with severe disability need to be identified in clinical settings and offered person-centered rehabilitation.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2225-2232"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China.","authors":"Weilin Xie, Qingyan Liu, Yanchun Tang, Yao Li, Yue Zhang, Shuhua Wang, Lin Wang","doi":"10.1007/s10067-025-07465-1","DOIUrl":"10.1007/s10067-025-07465-1","url":null,"abstract":"<p><strong>Objectives: </strong>Our pilot study investigated the efficacy and safety of tofacitinib (TOF) in patients with macrophage activation syndrome (MAS), providing a new therapeutic option.</p><p><strong>Methods: </strong>This was a historical comparator, single-center study. Patients enrolled in our study were screened using the 2016 Pediatric Rheumatology International Trials Organization (PRINTO) criteria of MAS. MAS patients deemed suitable for TOF therapy were enrolled in the experimental group. The control group included MAS patients from Yantai Yuhuangding Hospital who had received biological and/or conventional synthetic disease-modifying anti-rheumatic drugs (b/csDMARDs) treatment in a similar period. Clinical characteristics, laboratory test results, MAS treatment response rates, and glucocorticoid discontinuation rates were compared between the two groups before and after treatment. Serious adverse events such as thrombosis or severe infection were recorded.</p><p><strong>Results: </strong>A total of 36 MAS patients were included-17 in the TOF treatment group and 19 in the b/csDMARDs control group. Baseline demographic and clinical characteristics were comparable between groups. After six weeks, the proportion of febrile patients was significantly lower in the TOF group compared to the control group (11.8% [2/17] vs. 47.3% [9/19], P = 0.021). Significant reductions were also observed in C-reactive protein levels at week 6 (5.9% [1/17] vs. 36.8% [7/19], P = 0.026) and ferritin levels at week 12 (100.0% [17/17] vs. 26.3% [5/19], P = 0.023). The MAS treatment response rate was significantly higher in the TOF group at weeks 2 and 6 (P = 0.029 and P = 0.023, respectively). Glucocorticoid discontinuation was more frequent in the TOF group, with a 12-week discontinuation rate of 100.0% (17/17) compared to 57.9% (11/19) in the control group (P = 0.002). No serious adverse events, including thrombosis or severe infections, were reported.</p><p><strong>Conclusion: </strong>Our results suggest that TOF may be as effective as or even better than b/csDMARDs, with a quicker and higher response rate in patients with MAS without severe adverse events. Key Points •Tofacitinib may be as effective or better than b/csDMARDs in MAS. •Tofacitinib may act at a quicker and higher response rate in MAS. •Tofacitinib might be an alternative therapeutic option for patients with MAS.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2087-2093"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of hub-shared genes and regulatory mechanisms of rheumatoid arthritis and atherosclerosis.","authors":"Pei Zhao, Kexin Yuan, Zhipeng Tang, Yonghui Li, Yueqing Yu, Wei Gao, Yu Zhang, Jie Wang, Xinxin Li, Yanqing Tie","doi":"10.1007/s10067-025-07423-x","DOIUrl":"10.1007/s10067-025-07423-x","url":null,"abstract":"<p><strong>Objective: </strong>Study found that patients with rheumatoid arthritis (RA) are more likely to develop atherosclerosis than normal adults. However, their shared mechanisms of action still remain unclear. This study aimed to identify the shared genes between the two diseases and uncover their regulatory mechanisms.</p><p><strong>Method: </strong>The RA- and atherosclerosis-related microarray datasets were downloaded from public databases. Gene set enrichment, differential expression, and weighted gene co-expression network analyses were performed to identify the shared genes between the two diseases. Functional enrichment analysis and protein-protein interaction networks for shared genes were performed. Through further expression validation using validation datasets, hub-shared genes were identified. The diagnostic values of hub-shared genes and their related transcription factors (TFs), small-molecule drugs, and immune cells were analyzed.</p><p><strong>Results: </strong>A total of 82 shared genes, which were significantly involved in nine pathways, including the peroxisome proliferator-activated receptor signaling pathway and Th1 and Th2 cell differentiation, were identified. Two hub-shared genes, CD52 and TNFRSF17, were screened out using validation. CD52 and TNFRSF17 showed high diagnostic performance for both diseases. CD52 and TNFRSF17 could interact with multiple proteins, including TNFSF13, and are regulated by several TFs, including NFKB1 and MEF2A. Moreover, significant correlations were observed between hub-shared genes and the infiltration of several immune cells in the two diseases, such as between gamma delta T cells and TNFRSF17, as well as between neutrophils and CD52.</p><p><strong>Conclusion: </strong>Two hub-shared genes, CD52 and TNFRSF17, may be key regulators in the development of RA and atherosclerosis. Key Points • Study found that patients with RA are more likely to develop atherosclerosis. The shared mechanisms of action between the two diseases are unclear. We used bioinformatics methods to investigate shared genes and explore the mechanisms. • Our results indicated that the two hub genes, CD52 and TNFRSF17, may be key regulators in the development of atherosclerosis in RA. Further research of these two genes may reveal the mechanism that RA patients are more likely to suffer from atherosclerosis.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2241-2256"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study of electrocardiographic alterations in primary Sjögren's syndrome: role of anti-SSA positivity and disease duration.","authors":"Sibel Ösken, Altuğ Ösken, Fuat Polat, Duygu Şahin, Nihan Neval Uzun, Nesrin Şen, Mehmet Engin Tezcan","doi":"10.1007/s10067-025-07477-x","DOIUrl":"10.1007/s10067-025-07477-x","url":null,"abstract":"<p><strong>Background: </strong>Primary Sjögren's Syndrome (pSS) is a chronic autoimmune disorder affecting exocrine glands and potentially leading to cardiovascular complications. The impact of anti-SSA antibody seropositivity on cardiac function, particularly ECG parameters, is not well understood.</p><p><strong>Aims: </strong>This study aims to explore the association between anti-SSA antibody seropositivity and various ECG parameters, including the QT interval, corrected QT interval (QTc), QT dispersion, and T peak to T end (TP-TE) interval, in patients with pSS.</p><p><strong>Methods: </strong>A retrospective observational study was conducted involving 57 pSS patients. Participants were divided into seropositive (n = 32) and seronegative (n = 25) groups based on anti-SSA antibody status. ECG parameters were assessed, including QT interval, QTc interval, QT dispersion, and TP-TE interval. Statistical comparisons were made using independent t-tests, Mann-Whitney U tests, or chi-square tests, with a significance threshold of p < 0.05.</p><p><strong>Results: </strong>The seropositive group showed significantly prolonged QT interval (403.1 ± 28.7 ms) compared to the seronegative group (381.8 ± 28.2 ms, p < 0.01). Similarly, the QTc interval was longer in seropositive patients (430.1 ± 28.6 ms) compared to seronegative patients (412.6 ± 31.8 ms, p = 0.03). QT dispersion was greater in the seropositive group (43.5 ± 3.6 ms) compared to the seronegative group (40.8 ± 4.6 ms, p = 0.02). The TP-TE interval was also significantly prolonged in seropositive patients (67.9 ± 7.5 ms) compared to seronegative patients (63.4 ± 4.8 ms, p < 0.01). The TP-TE/QTc ratio did not differ significantly between the two groups.</p><p><strong>Conclusions: </strong>Anti-SSA seropositivity in pSS patients is associated with significant alterations in ECG parameters indicative of impaired ventricular repolarization. These findings suggest that seropositive pSS patients may have an increased risk of cardiovascular complications, emphasizing the importance of ECG monitoring in this patient population. Key Points •Anti-Ro/SSA seropositivity in pSS patients is linked to prolonged QT and QTc intervals, indicating impaired ventricular repolarization. •Seropositive pSS patients show increased QT dispersion, which may reflect a higher risk for arrhythmias. •The TP-TE interval is significantly prolonged in seropositive pSS patients, suggesting a higher risk for ventricular arrhythmias. •ECG monitoring is crucial in seropositive pSS patients to detect early cardiac abnormalities and guide treatment.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2377-2386"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor \"The association between dyslipidemia and hand osteoarthritis: a systematic review and meta-analysis\".","authors":"Xiaoling Li, Mengyun Long, Suifeng Yan, Yichen Zhang","doi":"10.1007/s10067-025-07441-9","DOIUrl":"10.1007/s10067-025-07441-9","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2589-2590"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of sarcopenia in patients with rheumatoid arthritis at a central university hospital in Hanoi, Vietnam: a cross-sectional study.","authors":"Thu Hoai Pham, Trang Thi Huyen Do, Tam Ngoc Nguyen, Linh Canh Luu, Huong Thi Tran, Thanh Xuan Nguyen, Thu Thi Hoai Nguyen, Huyen Thi Thanh Vu","doi":"10.1007/s10067-025-07469-x","DOIUrl":"10.1007/s10067-025-07469-x","url":null,"abstract":"<p><strong>Aim: </strong>To determine the prevalence and factors associated with sarcopenia in rheumatoid arthritis (RA) patients at a central university hospital in Hanoi, Vietnam.</p><p><strong>Methods: </strong>Patients with RA aged ≥ 18 were enrolled in this cross-sectional study. Dual-energy X-ray absorptiometry was performed to measure appendicular skeletal muscle (ASM). Assessment of muscle function included hand grip strength (HGS) and gait speed (GS). Sarcopenia was defined according to Asian Working Group for Sarcopenia (AWGS) criteria 2019. RA disease activity was evaluated by disease activity score 28 CRP (DAS28-CRP). Medical history and previous medications including steroids, methotrexate, bDMARDs, clinical characteristics, and comorbidities were also documented. Multivariable adjusted regression was used to examine potential factors associated with sarcopenia in patients with RA.</p><p><strong>Results: </strong>A total of 156 patients with RA were recruited, out of which the prevalence of sarcopenia was 62.82%. Among the participants, 95.16% had a low appendicular lean mass index (ALMI), 91.67% had low hand grip strength, and 36.54% had slow gait speed. Active RA disease was significantly associated with a higher odd ratio of having sarcopenia, low muscle mass, and low hand grip strength. After adjusting for potential factors, male (aOR 6.66), RA disease activity level (aOR 3.07), and hypertension (aOR 4.06) were statistically independent factors associated with sarcopenia.</p><p><strong>Conclusion: </strong>Effective RA management to achieve clinical remission is essential to mitigate sarcopenia risk. Further studies are essential to better understand sarcopenia and improve management in patients with RA. Key Points • Prevalence: Sarcopenia was present in 62.82% of patients with RA, especially in those with higher disease activity. • Risk Factors: Male gender, active disease, and hypertension were associated with sarcopenia. • Inflammation and disease activity: Active RA and elevated CRP levels were linked to reduced muscle mass and strength.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"2143-2151"},"PeriodicalIF":2.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}